drugset / Trial / NCT03960177

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

NCT03960177

NaSingle-groupOpen-labelTreatment

Summary

This early phase I trial studies how well glucarpidase works in reducing toxicity in patients with osteosarcoma receiving high dose methotrexate treatment. Glucarpidase may reduce the levels of methotrexate in patients' blood and lead to shorter hospitalizations and a reduction in toxicities.

Timeline

Start
2019-03-27
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Glucarpidase Protein / enzyme biologic 1000 iu Intravenous

Indications